

SPECTROPHOTOMETRIC DETERMINATION OF PHENYLBUTAZONE AND OXYPHENBUTAZONE THROUGH CONDENSATION WITH P-DIMETHYLAMINO BENZALDEHYDE

Gehard Rücker *, Magda Ayad, Mohamed El-Sadek and Samia Moustafa
Pharmacy Institute, Bonn University, Germany* and
Medicinal Chemistry Department, Faculty of Pharmacy,
Zagazig University, Egypt

ABSTRACT

P-Dimethylaminobenzaldehyde is used for colorimetric determination of phenylbutazone and oxyphenbutazone both in pure form and in their tablets. The reaction proceeds via first formation of aldol intermediate which suffers aminolysis by piperidine with subsequent elimination to afford intensive and stable colored disubstituted styrene. Beer's law is obeyed in the range of 0.08-0.4 mg mg^{-1} for phenylbutazone and 0.08-0.24 mg ml^{-1} for oxyphenbutazone.

INTRODUCTION

Phenylbutazone and oxyphenbutazone are used for the treatment of painful symptoms associated with gout, rheumatoid arthritis, rheumatoid spondylitis and painful shoulder⁽¹⁾. They were determined by bromometric titration, another method depends on titration with N-bromosuccinimide in acetic acid medium, also aqueous and non aqueous volumetric solution of sodium borohydride was used for their determination⁽²⁻⁴⁾. Spectrophotometric determination of these drugs were also reported in literature⁽⁵⁻¹⁰⁾.

EXPERIMENTAL

Materials, Reagents and Standards:

- Authentic phenylbutazone (El-Nile Co.).
- Authentic oxyphenbutazone (El-Nile Co.).
- Standard phenylbutazone 1 mg ml^{-1} in ethanol.
- Standard oxyphenbutazone 1 mg ml^{-1} in ethanol.
- Authentic P-dimethylaminobenzaldehyde.
- Standard P-dimethylaminobenzaldehyde 1 mg ml^{-1} in ethanol.
- Piperidine (Aldrich Co.).
- Alkazine tablets: Labelled to contain 100 mg Phenylbutazone per tablet.
- Romaxin tablets: Labelled to contain 100 mg oxyphenbutazone per tablet.
- Silica gel for column chromatography.

Apparatus:

Perkin-Elmer Lambda 2 UV/Vis spectrophotometer was used. ¹H NMR and ¹³C NMR spectra were carried out in pharmacy institute, Bonn University using ¹H NMR spectrometer T-60 (Varian).

A) Determination of phenylbutazone and oxyphenbutazone:

An accurately measured volumes of standard phenylbutazone solution (equivalent to 2-10 mg) or standard oxyphenbutazone solution (equivalent to 2-6 mg) were transferred into a 50 ml round flask. Exactly add 8 ml of standard P-dimethylaminobenzaldehyde for phenylbutazone or 6 ml for oxyphenbutazone, were added, completed to 25 ml with ethanol, then 0.2 ml piperidine for phenylbutazone and 0.5 ml for oxyphenbutazone, were added. The mixture was

refluxed for 100 and 70 minutes for phenylbutazone and oxyphenbutazone respectively.

The absorbance was measured at λ 386 nm for phenylbutazone and at λ 381 nm for oxyphenbutazone against blank experiments similarly prepared omitting phenylbutazone or oxyphenbutazone. The concentration was calculated of phenylbutazone or oxyphenbutazone from a standard curve prepared by the same procedures.

B) Determination of phenylbutazone and oxyphenbutazone tablets:

An accurately weighed amount of powdered contents of Alkazine or Romaxin tablets equivalent to 50 mg phenylbutazone or oxyphenbutazone was transferred into a beaker, dissolved in ethanol, filtered into a 50 ml volumetric flask, completed to volume with ethanol.

Different volumes of phenylbutazone solution (equivalent to 2-10 mg) or oxyphenbutazone solution (equivalent to 2-6 mg) were transferred into a 50 ml round flask. The procedure was completed as mentioned before.

RESULTS

The above described procedures were applied to:

i) Different concentrations of phenylbutazone and oxyphenbutazone. results were compared with those of the official B.P. methods,^(11,12) (Tables 1 & 2).

ii) Alkazine tablets, containing phenylbutazone and romaxin tablets containing oxyphenbutazone. The obtained results were compared with those of the official B.P. methods,^(13,14) (Tables 3 & 4).

DISCUSSION

Reaction of phenylbutazone and oxyphenbutazone under the proposed condition using P-dimethylaminobenzaldehyde and piperidine afforded products of modified absorption, thus allowing appropriate determination of these drugs. It seemed that

the reaction proceeds analogously to reaction of diazonium salt via first formation of Aldol intermediate which suffers aminolysis by piperidine with subsequent elimination to afford the stable intensively colored disubstituted styrene as shown in scheme 1:


These disubstituted styrenes have a yellow color which could be measured spectrophotometrically at 386 nm and 381 nm for phenylbutazone and oxyphenbutazone respectively.

Variables affecting the reaction were undertaken to develop maximum usefulness. Maximum absorption obtained when 8 ml of P-dimethylaminobenzaldehyde were added for phenylbutazone and 6 ml for oxyphenbutazone. Maximum absorption was obtained

when phenylbutazone was condensed with aldehyde for 100 minutes and oxyphenbutazone for 70 minutes.

The effect of piperidine volume was experimentally studied, and 0.2 ml for phenylbutazone and 0.5 ml for oxyphenbutazone were found optimum. Beer's law was obeyed in the range of 0.08-0.4 mgml⁻¹ for phenylbutazone and 0.08-0.24 mgml⁻¹ for oxyphenbutazone (Fig. 1).

The molar ratio of phenylbutazone and oxyphenbutazone to P-dimethylaminobenzaldehyde were determined by continuous variation method,⁽¹⁵⁻¹⁷⁾ which shows that the ratio is 1:1 for both phenylbutazone and oxyphenbutazone (Figs. 2&3). The color intensity of phenylbutazone and oxyphenbutazone with P-dimethylamino-benzaldehyde condensation products, was stable for one hour.



Scheme 1




Fig. (1): Colibration curve for phenylbutazone and oxyphenbutazone- P - dimethyl-aminobenzaldehyde condensation compounds.

The proposed method was successfully applied for the determination of phenyl-butazone and oxyphenbutazone. Recovery % obtained by the official method is better than that of the proposed method, but our method is more sensitive and could be applied for smaller sample amounts, (Tables 1&2). Alkazine and Romazin tablets were analysed by the suggested procedure.




Fig. (2): Continuous variation plot of phenylbutazone ($10^{-2}M$)-P-dimethylaminobenzaldehyde ($10^{-2}M$) reaction.




Fig. (3): Continuous variation plot of oxyphenbutazone ($2 \times 10^{-3}M$)-P-dimethylaminobenzaldehyde ($2 \times 10^{-3}M$) reaction.

Tables (3&4) indicate that, the proposed method is more sensitive than the official method, with sensitivity range (2-10 mg) for phenylbutazone and (2-6mg) for oxyphenbutazone compared with (50-250 mg) for the official method.

Statistical analysis of the results reveals that the suggested procedure is equally accurate and precise as the official method.

Isolation of the reaction products:

Column chromatography technique was used to separate the major reaction products.

Procedure for substance I:

The yellow-colored condensation product of phenylbutazone with P-dimethylaminobenzaldehyde was extracted with methylene chloride. Evaporation was carried out under reduced pressure, then chromatographed to give substance I, using (CH_2Cl_2 , EtOH, 9:1) as a developing system.

Spectral analysis of substance I:

The 1H NMR spectral data of substance I show signals at 1.24 (tr., 3H; C-6) 1.65 (m, 2H; C-5), 2.05 (quin, 2H; C-4), 2.87 (m, 2H; C-3), 3.13 (s, 6H; $N(CH_3)_2$), 3.72 (qr, 1H; C-2), 6.72 (d, 2H; C-8, 12) and 7.52 (d, 2H; C-9, 11).

^{13}C NMR spectral analysis of substance I:

^{13}C NMR spectrum of substance I, showed it 14 carbons, compared with 19 carbons for phenylbutazone and 9 carbons for P-dimethylaminobenzaldehyde. This spectrum has signals at δ 19.75 (C-6), 23.47 (C-5), 29.68 (C-4), 40.04 ($C_{13,14}$), 42, 40 (C-3), 111,80 ($C_{8,12}$), 121,33 (C_{10}), 121, 69 (C-2), 134.86 ($C_{9,11}$), 152.88 (C-1) and 155.32 (C-7). The UV spectrum of substance I has λ max. at 447.8 nm.

Comparison of ^1H NMR spectrum of substance I, with those of phenylbutazone and P-dimethylaminobenz, revealed:

- 1- Absence of the multiplet signal at (δ : 7.3) due to aromatic protons of phenylbutazone.
- 2- Disappearance of the triplet signal at (δ : 3.4) of C-4 hydrogen of phenyl-butazone.
- 3- Presence of the singlet signal at (δ : 3.1) integrating for $[-\text{N}(\text{CH}_3)_2]$ group of P-dimethylaminobenzaldehyde.

Spectral analysis of substance II:

Procedure for substance II:

The yellow colored condensation produce of oxyphenbutazone with P-dimethylaminobenzaldehyde was extracted with methylene chloride, evaporated under reduced pressure and chromatographed to give substance II using (CH_2Cl_2 -EtOH, 8:2) as a developing system.

Spectral analysis of substance II:

The ^1H NMR spectral data of substance II show signals at 1.23 (tr., 3H; C-6), 1.40 (m, 2H; C-5), 1.97 (m, 2H; C-4), 2.85 (m, 2H; C-3), 3.10 (s, 6H; $\text{N}(\text{CH}_3)_2$), 3.70 (qr, H; C-2), 5.30 (s, H; C-1), 6.70 (d, 2H; $\text{C}_{(8,12)}$) and 7.50 (d, 2H, $\text{C}_{-(9,11)}$).

Comparison of ^1H NMR spectrum of substance II, with those of oxyphenbutazone and P-dimethylaminobenzaldehyde revealed:

- i- Absence of the doublet signals at (δ = 6.6 87) and multiplet signal at (δ = 7.3) due to aromatic protons of oxyphenbutazone.
- ii- Disappearance of the triplet signal at (δ = 3.4) of C-4 hydrogen of oxyphenbutazone.
- iii- Presence of the singlet signal at (δ = 3.1) integrating for $[-\text{N}(\text{CH}_3)_2]$ group of P-dimethylaminobenzaldehyde.

Table (1): Determination of phenylbutazone using the proposed method compared with the official B.P. (1988) method.

Official Method			Proposed Method		
Taken (mg)	Found (mg)	Recovery* (%)	Taken (mg)	Found (mg)	Recovery* (%)
50	49.96	99.92	2	1.98	99.47
100	100.53	100.53	4	3.95	98.95
150	149.80	99.87	6	5.99	99.94
200	199.84	99.92	8	7.85	98.23
250	248.12	99.25	10	9.96	99.59
Mean recovery \pm S.D.		99.98 \pm 0.45			5
(P = 0.05)					99.24 \pm 0.67
N					5
t					1.81 (2.30)
F					2.15 (5.05)

* Average of 3 experiments.

Table (2): Determination of oxyphenbutazone using the proposed method compared with the official B.P. (1988) method.

Official Method			Proposed Method		
Taken (mg)	Found (mg)	Recovery* (%)	Taken (mg)	Found (mg)	Recovery* (%)
50	49.81	99.62	2	1.97	98.38
100	100.86	100.86	3	2.97	98.98
150	148.98	99.32	4	3.99	99.74
200	199.16	99.08	5	4.98	99.68
250	247.87	99.15	6	5.95	99.13
Mean recovery \pm S.D.		99.61 \pm 0.73			5
(P = 0.05)					99.18 \pm 0.56
N					5
t					1.05 (2.30)
F					1.72 (5.05)

* Average of 3 experiments.

Table (3): Determination of oxyphenbutazone in Alkazine using the proposed method and the official B.P. (1988) method.

Official Method			Proposed Method		
Taken (mg)	Found (mg)	Recovery* (%)	Taken (mg)	Found (mg)	Recovery* (%)
50	50.31	100.62	2	1.97	98.71
100	99.92	99.92	4	3.97	99.23
150	149.17	99.45	6	5.94	99.15
200	199.36	99.56	8	7.95	99.35
250	248.15	99.26	10	9.91	99.11
Mean recovery \pm S.D.		99.79 \pm 0.53			5
(P = 0.05)					99.11 \pm 0.24
N					5
t					2.62 (2.30)
F					4.77 (5.05)

* Average of 3 experiments.

Table (4): Determination of oxyphenbutazone using the proposed method compared with the official B.P. (1988) method.

Official Method			Proposed Method		
Taken (mg)	Found (mg)	Recovery* (%)	Taken (mg)	Found (mg)	Recovery* (%)
50	49.35	98.69	2	1.97	98.46
100	99.51	99.51	3	2.97	98.95
150	148.86	99.24	4	3.97	99.32
200	198.74	99.37	5	4.96	99.31
250	248.03	99.25	6	5.96	99.26
Mean recovery \pm S.D.		99.21 \pm 0.31			5
(P = 0.05)					99.06 \pm 0.37
N					5
t					0.70 (2.30)
F					11.40 (5.05)

* Average of 3 experiments.

REFERENCES

- 1- Wislon C.D.; Gisvold, O. and Doerge, R.F.: "Textbook of organic medicinal and pharmaceutical chemistry", 7th ed., J.b. Lippincott Company, PP., 724-726(1977).
- 2- Sebkova, D. and Safarik, L.: J. Assoc. Off. Anal. Chem. 69 (2), 191-200 (1986).
- 3- Taha, A.M.; El-Zeany, B.A. and El-Sawy: Egypt. J. Pharm. Sci. 22 (1-4), 47-53 (1981).
- 4- Bezakova, Z.; Bachrata, M. and Knazko, L. (1978): Acta Fac. Pharm. Univ. Comeniane, 32, 109. Through C.A. 93: 31839e (1980).
- 5- Morait, Gh.; Turculet, V.; Popa, C. and Petronium, L. Farmacia, 37(1), 1-8, (1989). Through C.A. 112: 145658m (1990)
- 6- Carmona, M.; Silva, M. and Perez-Bendit, D. Fresenius, Z. Anal. Chem., 334 (3), 261-5, (1989). Through C.A. III: 160391 P. (1989). Job, P.; Ann. Chim, 6, 97. (1936)
- 7- Parimoo, P. Indian Drugs, 26(6), 276-9, 91989) Through C.A. 119: 218933t (1989).
- 8- Belal, S.; El-Kheir, A.A. and El-Shanwani, A.M. Anal. Lett. 18 (B5), 617-28 (1985).
- 9- El-Kheir, A.A.; Belal, S. and El-Shanwani Pharmazie, 40 (1), 62 (1985).
- 10- Belal, S.; El-Kheir, A.A. and El-Shanwani, A.M., Analyst (London), 110 (2), 205-8 (1985).
- 11- The British Pharmacopeia, The Pharmaceutical press, London Her Majesty's Stationary Office, Vol. 1, 436 (1988).
- 12- Ibid, V, I, 1, 408-409 (1988).
- 13- Ibid, Vol. II, 986 (1988).
- 14- Ibid, Vol. II, XXX III, (1988).
- 15- Rose, J. Advanced Physico-Chemical Experiments" Pitman, London, England, 54, 1964.
- 16- Vosburgh, W.C. and Cooper, G. R.: J. Amer. Chem. Soc. 63: 437 (1941).
- 17- Job, P., Ann. Chim., 6, 97, 1936.

Received: 27 March 1997

Accepted: 17 June 1997

التقدير الطبقي لمركب الفينيل بيوتازون والأوكس فينبيوتازون من خلال تفاعلهم مع ٤- ثنائي ميثيل أمينوبنزالدهيد

جيهارد روكو* - ماجدة عياد - محمد الحسيني الصادق - سامية مصطفى

قسم الكيمياء الصيدلانية - كلية الصيدلة - جامعة الزقازيق

* ومعهد الصيدلة - جامعة بون - ألمانيا

في هذا البحث تم تحليل كل من الفينيل بيوتازون والأوكس فينبيوتازون بطريقة طيفية جديدة تعتمد على تفاعلهم مع ٤- ثنائي ميثيل أمينوبنزالدهيد في وجود البييريدين. وقد طلبت الطريقة المقترحة على المستحضرات الصيدلانية (أقراص الالكازون والروماكسين)، وبمقارنة الطريقة المقترحة بالطريقة الدستورية وجد أن هذه الطريقة أكثر دقة ويمكن استخدامها في تقدير كميات أصغر من المادة.